BIT Capital GmbH Has $309,000 Holdings in Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL)

Key Points

• BIT Capital GmbH has reduced its stake in Autolus Therapeutics by 68.7%, selling 437,620 shares to hold 199,359 shares valued at approximately $309,000.
• Institutional investors currently own 72.83% of Autolus Therapeutics, with notable increases in positions by Barclays PLC and Bayesian Capital Management.
• Analysts have a consensus "Buy" rating for Autolus Therapeutics with an average price target of $9.32, despite the stock experiencing a recent decline of 2.1%.

BIT Capital GmbH lessened its holdings in shares of Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Free Report) by 68.7% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 199,359 shares of the company's stock after selling 437,620 shares during the period. BIT Capital GmbH owned approximately 0.07% of Autolus Therapeutics worth $309,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in AUTL. Virtus ETF Advisers LLC increased its stake in Autolus Therapeutics by 29.9% during the fourth quarter. Virtus ETF Advisers LLC now owns 26,429 shares of the company's stock valued at $62,000 after acquiring an additional 6,081 shares during the period. Barclays PLC grew its stake in shares of Autolus Therapeutics by 1,094.3% in the 4th quarter. Barclays PLC now owns 11,859 shares of the company's stock valued at $28,000 after purchasing an additional 10,866 shares during the period. Jane Street Group LLC bought a new stake in shares of Autolus Therapeutics in the 4th quarter valued at approximately $26,000. Two Sigma Advisers LP grew its stake in shares of Autolus Therapeutics by 4.8% in the 4th quarter. Two Sigma Advisers LP now owns 333,400 shares of the company's stock valued at $783,000 after purchasing an additional 15,400 shares during the period. Finally, Privium Fund Management B.V. boosted its position in Autolus Therapeutics by 8.6% in the 1st quarter. Privium Fund Management B.V. now owns 251,674 shares of the company's stock valued at $390,000 after buying an additional 20,000 shares during the last quarter. Institutional investors and hedge funds own 72.83% of the company's stock.

Analyst Ratings Changes

Separately, Needham & Company LLC reiterated a "buy" rating and issued a $10.00 price objective on shares of Autolus Therapeutics in a research report on Monday, July 21st. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $9.32.

Autolus Therapeutics Stock Down 0.3%

Autolus Therapeutics stock traded down $0.01 during mid-day trading on Thursday, hitting $2.30. 371,857 shares of the company's stock were exchanged, compared to its average volume of 1,756,008. The firm has a market capitalization of $613.19 million, a P/E ratio of -2.61 and a beta of 1.90. Autolus Therapeutics PLC Sponsored ADR has a fifty-two week low of $1.11 and a fifty-two week high of $5.00. The company's 50 day simple moving average is $2.30 and its 200-day simple moving average is $1.90.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.02). The company had revenue of $8.98 million during the quarter, compared to analyst estimates of $1.59 million. Research analysts expect that Autolus Therapeutics PLC Sponsored ADR will post -0.94 EPS for the current year.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.